妍美生物港股IPO招股书失效

Core Viewpoint - Oriental Yanmei (Chengdu) Biotechnology Co., Ltd. has submitted its Hong Kong IPO prospectus, which has now expired after six months, with Jianyin International as the sole sponsor [1]. Group 1: Company Overview - Yanmei Biotechnology was established in 2016 and focuses on the research, development, production, and commercialization of regenerative medical devices and special medical foods [2]. - The company specializes in the development, transformation, and application of regenerative medical materials, as well as the research and development of specific all-nutrition formula foods [2]. - Yanmei Biotechnology has accumulated key technologies in the research, modification, and preparation of polymer materials and regenerative biomaterials, including the development and preparation of microspheres [2]. Group 2: Product Lines - The company has the capability to transform regenerative medical material technologies into mature products that meet market demands [2]. - As a platform enterprise for regenerative medical material technology, Yanmei Biotechnology has a strong product portfolio that includes two main product lines: regenerative medical material injectables and medical dressings and patches made from regenerative medical materials [2].